Evidence map›Paper›PMID 23818854›Full record

Trial reportPLoS pathogens2013

The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation.

Mathieu F Chevalier, Gaël Petitjean, Catherine Dunyach-Rémy, Céline Didier, Pierre-Marie Girard, Maria Elena Manea, Pauline Campa, Laurence Meyer, Christine Rouzioux, Jean-Philippe Lavigne and 3 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Increased Platelet-CD4Frontiers in immunology · 2021
    Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Mathieu F ChevalierInstitut Pasteur, Régulation des Infections Rétrovirales, Paris, France.
Gaël Petitjean
Catherine Dunyach-Rémy
Céline Didier
Pierre-Marie Girard
Maria Elena Manea
Pauline Campa
Laurence Meyer
Christine Rouzioux
Jean-Philippe Lavigne
Françoise Barré-Sinoussi
Daniel Scott-Algara
Laurence Weiss
Institut Pasteur · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Nîmes · FRCentre de recherche en Epidémiologie et Santé des Populations · FRDélégation Paris 5 · FRHôpital Européen Georges-Pompidou · FRHôpital Necker-Enfants Malades · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Impairment of the intestinal barrier and subsequent microbial translocation (MT) may be involved in chronic immune activation, which plays a central role in HIV pathogenesis. Th17 cells are critical to prevent MT. The aim of the study was to investigate, in patients with primary HIV infection (PHI), the early relationship between the Th17/Treg ratio, monocyte activation and MT and their impact on the T-cell activation set point, which is known to predict disease progression. 27 patients with early PHI were included in a prospective longitudinal study and followed-up for 6 months. At baseline, the Th17/Treg ratio strongly negatively correlated with the proportion of activated CD8 T cells expressing CD38/HLA-DR or Ki-67. Also, the Th17/Treg ratio was negatively related to viral load and plasma levels of sCD14 and IL-1RA, two markers of monocyte activation. In untreated patients, the Th17/Treg ratio at baseline negatively correlated with CD8 T-cell activation at month 6 defining the T-cell activation set point (% HLA-DR(+)CD38(+) and %Ki-67(+)). Soluble CD14 and IL-1RA plasma levels also predicted the T-cell activation set point. Levels of I-FABP, a marker of mucosal damages, were similar to healthy controls at baseline but increased at month 6. No decrease in anti-endotoxin core antibody (EndoCAb) and no peptidoglycan were detected during PHI. In addition, 16S rDNA was only detected at low levels in 2 out 27 patients at baseline and in one additional patient at M6. Altogether, data support the hypothesis that T-cell and monocyte activation in PHI are not primarily driven by systemic MT but rather by viral replication. Moreover, the "innate immune set point" defined by the early levels of sCD14 and IL-1RA might be powerful early surrogate markers for disease progression and should be considered for use in clinical practice.

Indexed as

Bacterial TranslocationHIV-1Lymphocyte ActivationBase SequenceBiomarkersCD8-Positive T-LymphocytesDNA, BacterialDNA, RibosomalFatty Acid-Binding ProteinsFemaleHIV InfectionsHumansInterleukin 1 Receptor Antagonist ProteinIntestinal MucosaLipopolysaccharide ReceptorsMaleBiomarkersDNA, BacterialDNA, RibosomalFatty Acid-Binding ProteinsIL1RN protein, humanInterleukin 1 Receptor Antagonist ProteinLipopolysaccharide Receptors

Identifiers

PMID23818854
PMCPMC3688532
OpenAlexW2045995185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.